# OCS-01 in Treating Inflammation and Pain in Post-cataract Patients

> **NCT04130802** · PHASE2 · COMPLETED · sponsor: **Oculis** · enrollment: 153 (actual)

## Conditions studied

- Inflammation Corneal
- Pain, Postoperative

## Interventions

- **DRUG:** OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04130802
- **Lead sponsor:** Oculis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-27
- **Primary completion:** 2020-01-31
- **Final completion:** 2020-01-31
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04130802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04130802, "OCS-01 in Treating Inflammation and Pain in Post-cataract Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04130802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*